Bile acid therapy for primary biliary cholangitis: Pathogenetic validation

doi:10.5493/wjem.v15.i1.101771

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

This Article

(186)

(161)

(0)

(15)

(6318)

(3)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Experimental Medicine

ISSN

2220-315x

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Exp Med. Mar 20, 2025; 15(1): 101771
Published online Mar 20, 2025. doi: 10.5493/wjem.v15.i1.101771

Full Size Figure Download Figure

Figure 4 Cholehepatic bypass and metabolism of norursodeoxycholic acid glucuronide. norUDCA: Norursodeoxycholic acid glucuronide; MRP: Multidrug-resistance protein.

Citation: Reshetnyak VI, Maev IV. Bile acid therapy for primary biliary cholangitis: Pathogenetic validation. World J Exp Med 2025; 15(1): 101771
URL: https://www.wjgnet.com/2220-315x/full/v15/i1/101771.htm
DOI: https://dx.doi.org/10.5493/wjem.v15.i1.101771

Reshetnyak VI, Maev IV. Bile acid therapy for primary biliary cholangitis: Pathogenetic validation. World J Exp Med 2025; 15(1): 101771 [PMID: 40115760 DOI: 10.5493/wjem.v15.i1.101771]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.